Table 1.
Demographic and clinical variables
| Healthy control subjects (n = 14) | Cognitively normal patients with Parkinson’s disease (n = 11) | Patients with Parkinson’s disease with MCI (n = 11) | |
|---|---|---|---|
| Age in years (SD) | 67.5 (7.43) | 68.8 (3.71) | 70.8 (7.01) |
| Education in years (SD) | 17.1 (2.74) | 15.7 (2.87) | 16.2 (1.47) |
| Male/female | 3M/11F | 3M/8F | 8M/3F |
| Unified Parkinson’s Disease Rating Scale-III | – | 23.3 (12.03) | 31.45 (18.5) |
| Disease duration in years (SD) | – | 6.3 (4.20) | 7.1 (3.42) |
| LEDD total (mg/day) | – | 725 (570.85) | 663.7 (397.53) |
| Dopamine agonist LEDD (mg/day) | – | 166.67 (28.87) | 216.67 (160.73) |
| Montreal Cognitive Assessment | 27.6 (2.21) | 26.5 (1.81) | 23.2 (2.79)a |
| Beck Depression Inventory | 4 (3.85) | 5.9 (1.87) | 5.54 (5.87) |
SD = standard deviation; LEDD = levodopa equivalent daily dose.
Values are listed as mean (SD).
a
Independent sample t-tests were used to compare demographic variables between groups. The patients with Parkinson’s disease with MCI group had significantly lower Montreal Cognitive Assessment scores than healthy control subjects (P < 0.001) and cognitively normal patients (P < 0.01). There were no significant differences in age, education, Unified Parkinson’s Disease Rating Scale III, disease duration, levodopa equivalent daily dose (calculated according to Evans. et al., 2004) or Beck Depression Inventory.